Ana Radeljevic
Direktor/Vorstandsmitglied bei MERRIMACK PHARMACEUTICALS, INC.
Vermögen: 61 218 $ am 30.04.2024
Profil
Ana Radeljevic is currently the Chief Executive Officer at Adventus Partners since 2016.
She is also an Independent Director at Merrimack Pharmaceuticals, Inc. since 2022 and the Chief Business Officer at ADRx, Inc. since 2021.
Previously, she worked as the Vice President-Financial Planning & Analysis at Revvity, Inc. from 2014 to 2016.
Ms. Radeljevic holds an MBA from Syracuse University and an undergraduate degree from Old Dominion University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 15.03.2024 | 4 156 ( 0,03% ) | 61 218 $ | 30.04.2024 |
Aktive Positionen von Ana Radeljevic
| Unternehmen | Position | Beginn |
|---|---|---|
| MERRIMACK PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 06.06.2022 |
ADRx, Inc.
 ADRx, Inc. Pharmaceuticals: MajorHealth Technology ADRx, Inc. is a biopharmaceutical company. The firm advances drug candidates for Alzhiemer’s disease, systemic amyloidosis and ovarian cancer. The company was founded by Gary Wilcox and David Eisenberg and is headquartered in Thousand Oaks, CA. | Corporate Officer/Principal | 01.09.2021 |
Ehemalige bekannte Positionen von Ana Radeljevic
| Unternehmen | Position | Ende |
|---|---|---|
| REVVITY, INC. | Corporate Officer/Principal | 01.01.2016 |
Ausbildung von Ana Radeljevic
| Syracuse University | Masters Business Admin |
| Old Dominion University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| MERRIMACK PHARMACEUTICALS, INC. | Health Technology |
| REVVITY, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
ADRx, Inc.
ADRx, Inc. Pharmaceuticals: MajorHealth Technology ADRx, Inc. is a biopharmaceutical company. The firm advances drug candidates for Alzhiemer’s disease, systemic amyloidosis and ovarian cancer. The company was founded by Gary Wilcox and David Eisenberg and is headquartered in Thousand Oaks, CA. | Health Technology |
